Skip to main content

Table 3 Adjusted risk differences for co-primary outcomes after matching by propensity scorea

From: Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study

Outcomes within 30 days

BA.1 (n = 14)

BA.2 (n = 14)

Adjusted risk difference, BA.2 minus BA.1 (95% CI)

P valueb

Hospitalization due to COVID-19

3 (21.4%)

1 (7.1%)

− 14.3% (− 32.6 to 4.0%)

0.5956

All-cause ICU admission

1 (7.1%)

0 (0%)

− 7.1% (− 20.6 to 6.3%)

> 0.9999

All-cause mortality

1 (7.1%)

0 (0%)

− 7.1% (− 20.6 to 6.3%)

> 0.9999

  1. aMatched prognostic factors: age, sex, vaccination status, immunocompromised status, and number of risk factors for progression to severe COVID-19
  2. bP values computed from Fisher’s exact test